HuiHe Healthcare Raises ￥10M in Angel Round of Financing

According to VCBeat, Shanghai HuiHe Healthcare Technology Co., Ltd. ("HuiHe Healthcare") has announced the completion of its angel round of tens of millions yuan, led by Oriza Seed Capital. Huaxing Alpha acts as the financial advisor for this financing. This round is a milestone for HuiHe Healthcare. Proceeds from this financing will be used for the mass production and various cooperation with partners of Huihe Medical.

HuiHe Healthcare focuses on the R&D and production of the interventional medical devices for structural heart disease. The company has independently developed its core product, the tricuspid valve repair system.

Tricuspid valvuloplasty is currently the preferred surgical procedure for the treatment of functional tricuspid regurgitation in cardiac surgery at home and abroad. The most classic Kay's annuloplasty is not only used in the surgical approach using annuloplasty rings, but also widely used in the interventional therapy of structural heart disease. 

Based on Kay's annuloplasty, HuiHe Healthcare independently developed K-Clip, the world's first interventional instrument for tricuspid valve repair with ultrasonic positioning, to reduce the injury and let patients recover quickly. At the same time, the product has a wider indication. Patients with severe tricuspid regurgitation and moderate or less pulmonary hypertension can use it.

Lin Lin, the founder of HuiHe Healthcare, said, "Kay's procedure adopted by K-Clip has been used for decades in cardiac surgery, for which it can reduce the risk of patients. K-Clip can also effectively reduce the requirements of the operating room, the radiation exposure of medical staff and shorten the learning curve of doctors. This round of financing will promote our development and certification of our tricuspid valve repair system, as well as the development of other pipelines related to structural heart disease."

Oriza Seed, located in Suzhou Industrial Park, is held by Suzhou Oriza Holdings Ltd. It looks for investment opportunities among early-stage and growth-stage enterprises in the fields of healthcare and TMT. Oriza Seed has ample resources and experiences investing in the healthcare field. By late March 2016, Oriza Seed has invested in more than 50 healthcare companies.

Huaxing Alpha is a subsidiary of Huaxing Capital Group, providing private equity advisory services for enterprises in the early stage. The company has helped more than 300 companies complete the start-up financing of nearly 14 billion yuan.